Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party
Authors:
- J WachowiakJWJ Wachowiak
- J R KowalczykJKJ R Kowalczyk
- C PetersCPC Peters
- On Behalf Of The Ebmt Pediatric Diseases Working PartyOPOn Behalf Of The Ebmt Pediatric Diseases Working Party
- 7 February 2011
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (12) , 1510-1518
Abstract
This retrospective analysis evaluated 51 children (0.7-17 years; median eight) with high-risk or advanced hematological malignancies, including 18 (35%) patients undergoing second/third hematopoietic SCT (allo-HSCT), not eligible for standard myeloablative regimens and transplanted from matched sibling (MSD) (n=24) or matched unrelated (MUD) (n=27) donors. Preparative regimens were based on treosulfan (TREO) i.v., a structural analog of BU, given at total dose of 30 g/m(2) (n=21) or 36-42 g/m(2) (n=30) in combination with, fludarabine, cyclophosphamide, melphalan and/or VP-16 according to diagnosis, and risk factors. Deaths due to early regimen-related toxicity (RRT) did not occur. Nonrelapse mortality was 8% at 1 year and 16% after 4 years. Myeloid engraftment was achieved in 94%, complete donor chimerism in 90% of patients. A 4-year incidence of relapse was 24%, and was significantly lower after MUD-HSCT (8%) than after MSD-HSCT (39%), but similar in children undergoing first (28%) or second/third HSCT (17%). A 4-year disease-free survival was 61%, but it was significantly better in myeloid (73%), than in lymphoid malignancies (41%). Thus, children with high-risk and advanced hematological malignancies and high-risk of life-threatening RRT can be transplanted effectively and safely using TREO-based regimens. Particularly favorable results were achieved in myeloid malignancies and in children undergoing second HSCT.Keywords
This publication has 38 references indexed in Scilit:
- Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCTBone Marrow Transplantation, 2008
- Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high-risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study ReportTransplantation and Cellular Therapy, 2007
- Cytotoxicity of treosulfan and busulfan on pediatric tumor cell linesAnti-Cancer Drugs, 2006
- Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)Bone Marrow Transplantation, 2006
- Secondary malignancies and quality of life after stem cell transplantationBone Marrow Transplantation, 2005
- The hope and the reality of reduced intensity transplants in children with malignant diseasesBone Marrow Transplantation, 2005
- Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A Pediatric Blood and Marrow Transplant Consortium studyBone Marrow Transplantation, 2003
- Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioningBone Marrow Transplantation, 2003
- Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)Seminars in Liver Disease, 2002
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988